Abstract
Immunotoxins composed of cell-selective ligands covalently linked to peptide toxins have been developed for the treatment of chemotherapy relapsed or refractory malignancies including chronic lymphocytic leukemia (CLL). A number of CLL immunotoxins have been clinically tested including T101-ricin A, H65-ricin A, DAB 486 IL2, DAB 389 IL2, RFB4 (dsFv)-PE38 and anti-Tac(Fv)-PE38. Remissions have occurred in some patients without significant myelosuppression, but novel agents continue to be needed. Kay and co-workers in this issue of Leukemia Research have targeted interleukin-4 receptors (IL4R) on CLL B cells with a recombinant IL4 pseudomonas exotoxin fusion protein (IL-4(38-37)-PE38KDEL). A fraction of patients (19%) had CLL cells that were extremely sensitive to the immunotoxin. This novel agent may provide an important new therapeutic for use in the treatment of CLL.
Original language | English (US) |
---|---|
Pages (from-to) | 985-986 |
Number of pages | 2 |
Journal | Leukemia Research |
Volume | 29 |
Issue number | 9 |
DOIs | |
State | Published - Sep 2005 |
Keywords
- CLL
- Immunotoxins
- Leukemia
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research